ABCZY:OTC-Abcam plc (USD)

COMMON STOCK | Biotechnology | OTC

Last Closing Price

USD 23.08

Change

0.00 (0.00)%

Market Cap

USD 4.35B

Volume

0.22M

Avg Analyst Target

N/A

Avg User Target

USD
Average Analyst Rating

N/A

Fundamental Analysis

Verdict


Abcam plc (ABCZY) Stock Analysis:
Based on the Abcam plc stock forecasts from 0 analysts, the average analyst target price for Abcam plc is not available over the next 12 months. Abcam plc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Abcam plc is Very Bullish, which is based on 2 positive signals and 0 negative signals. At the last closing, Abcam plc’s stock price was USD 23.08. Abcam plc’s stock price has changed by +0.00% over the past week, +0.00% over the past month and +0.00% over the last year.

No recent analyst target price found for Abcam plc
No recent average analyst rating found for Abcam plc

About

Abcam plc, a life sciences company, researches, develops, and distributes biological reagents and tools for research, drug discovery, and diagnostics in the United States, China, Japan, Europe, the Middle East, Africa, and rest of Asia Pacific. The company offers various research ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-05-16 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
NONOF Novo Nordisk A/S

-4.00 (-3.72%)

USD236.97B 35.86 3.53
AKABY ALK-Abelló A/S

N/A

USD94.78B 3,123.91 7.56
CSLLY CSL Limited

-0.82 (-0.84%)

USD94.74B 38.38 26.40
CMXHF CSL Limited

-0.18 (-0.09%)

USD93.59B 38.21 26.14
WXXWY WuXi Biologics (Cayman) Inc

+0.12 (+0.92%)

USD30.13B 57.56 6.03
WXIBF WuXi Biologics

+0.52 (+8.18%)

USD28.74B 55.30 6.03
GNMSF Genmab A/S

-2.67 (-0.92%)

USD20.42B 45.11 3.87
UCBJF UCB SA

+1.25 (+1.37%)

USD17.72B 15.85 13.14
UCBJY UCB SA

+0.47 (+1.03%)

USD17.29B 16.15 13.14
SBHMY Sino Biopharmaceutical Limited

N/A

USD9.76B 4.80 0.44

ETFs Containing ABCZY

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain 79.33% N/A N/A N/A N/A
Dividend Return 2.74% N/A N/A N/A N/A
Total Return 82.07% N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 13.64% N/A N/A N/A N/A
Dividend Return 0.49% N/A N/A N/A N/A
Total Return 14.13% N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 21.34% N/A N/A N/A N/A
Risk Adjusted Return 66.22% N/A N/A N/A N/A
Market Capitalization 4.35B N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 48.62 N/A N/A N/A N/A
Price/Book Ratio 5.13 N/A N/A N/A N/A
Price / Cash Flow Ratio 69.05 N/A N/A N/A N/A
EV/EBITDA 141.88 N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -0.37% N/A N/A N/A N/A
Return on Invested Capital 2.94% N/A N/A N/A N/A
Return on Assets 2.94% N/A N/A N/A N/A
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Dividend Yield 0.80% N/A N/A N/A N/A
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 0.40 N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:

There is nothing we particularly dislike